Loading…
GeoVax Labs, Inc. is projected to decline to $1.06 by 2027, a -10% move from its current price of $1.18. GOVX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/13/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 15 | $1.11 | $1.18 | $1.25 | +0.08% |
| Jul 16 | $1.08 | $1.18 | $1.29 | +0.15% |
| Jul 17 | $1.07 | $1.18 | $1.31 | +0.23% |
| Jul 18 | $1.05 | $1.18 | $1.34 | +0.30% |
| Jul 19 | $1.03 | $1.18 | $1.36 | +0.38% |
| Jul 20 | $1.02 | $1.19 | $1.37 | +0.46% |
| Jul 21 | $1.01 | $1.19 | $1.39 | +0.53% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.01 | $1.19 | $1.39 | +0.53% |
| Week 2 | $0.9511 | $1.19 | $1.50 | +1.07% |
| Week 3 | $0.9088 | $1.20 | $1.58 | +1.60% |
| Week 4 | $0.8753 | $1.21 | $1.66 | +2.14% |
| Week 5 | $0.8474 | $1.21 | $1.73 | +2.69% |
| Week 6 | $0.8233 | $1.22 | $1.80 | +3.23% |
| Week 7 | $0.8021 | $1.22 | $1.87 | +3.78% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
GeoVax Labs, Inc. is a clinical-stage biotechnology company that develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. It is based in Smyrna, Georgia, and GeoVax Labs, Inc. was incorporated in 1988.
The company develops GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, the company offers GEO-MVA-MUC1, a vaccine candidate, which is in preclinical trial for the treatment of solid tumor cancers; GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-EMO1-Z, which is in preclinical trial for the treatment of Ebola Zaire; GEO-EMO1-S, which is in preclinical trial for the treatment of Ebola Sudan; GEO-MM01 treatment for marburg; and GEO-MVA for the treatment of Mpox and small pox. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; and the U.S.
Department of Defense.
GeoVax Labs, Inc. (GOVX) is a small-cap biotechnology stock with a current price of $1.19 and a market cap of $6.2M. It is ranked 5112 by market capitalization.
The stock’s price outlook, according to the provided forecast, shows a range of outcomes across years. The 2026 forecast places the average near $1.19, with a min of $1.05 and a max of $1.72. The long-run forecast extends to 2050, with the 2050 average projected at $3.45 and a max of $7.94, reflecting a wide potential trajectory from near-term softness to multi-year upside.
A major floor 71.2% below — a decisive break under it would weaken the trend.
Price is testing support right now (1.7% away) — a key level to hold.
The nearest ceiling, 103.4% above — a clean break opens room to run.
A major ceiling 208.5% above — clearing it would confirm fresh momentum.
Key GOVX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of GOVX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.19 | Sell | $1.19 | Sell |
| MA 10 | $1.23 | Sell | $1.22 | Sell |
| MA 20 | $1.24 | Sell | $1.31 | Sell |
| MA 50 | $1.59 | Sell | $1.52 | Sell |
| MA 100 | $1.52 | Sell | $2.45 | Sell |
| MA 200 | $5.23 | Sell | $7.18 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 40.75 | Neutral |
| Stoch RSI (14) | 19.53 | Buy |
| CCI (20) | -68.89 | Neutral |
| Williams %R (14) | -90.91 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | -8.53 | Sell |
| Bollinger %B (20,2) | 0.27 | Neutral |
| Stochastic %K (14) | 9.09 | Buy |
| TRIX (15) | -1.31 | Sell |
| Awesome (5,34) | -0.44 | Sell |
| Ultimate (7,14,28) | 32.11 | Neutral |
| Momentum (10) | -0.13 | Sell |
| Aroon Osc (25) | -92.00 | Sell |
| Hull MA (9) | 1.15 | Buy |
| ADX (14) | 18.13 | Neutral |
| ATR (14) | 0.08 | Info |
The near-term technical picture is NEUTRAL. The RSI(14) is 40, indicating room for momentum to shift without being overbought or oversold.
The 50-day simple moving average is $1.59 and the 200-day simple moving average is $5.61, signaling mixed trend dynamics given the price level. Support is at $1.17 and resistance at $3.64, outlining a tight near-term trading band.
Over the last 30 days, the price has traded within a range from $0.7571 to $1.87, illustrating a modestly wide swing within the context of a fragile near-term setup.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.05 | $1.18 | $1.68 | 0% | Neutral | |
| $0.7682 | $1.06 | $1.58 | -10% | Neutral | |
| $0.6735 | $0.9863 | $1.57 | -16% | Bearish | |
| $0.6209 | $0.9579 | $1.60 | -19% | Bearish | |
| $0.6246 | $1.01 | $1.75 | -14% | Neutral | |
| $0.7753 | $1.31 | $2.35 | +11% | Neutral | |
| $0.7886 | $1.39 | $2.58 | +18% | Neutral | |
| $0.8042 | $1.48 | $2.81 | +25% | Bullish | |
| $0.7048 | $1.35 | $2.63 | +14% | Neutral | |
| $0.5301 | $1.05 | $2.10 | -11% | Neutral | |
| $0.757 | $1.68 | $3.69 | +43% | Bullish | |
| $1.50 | $3.34 | $7.69 | +183% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $1.05 | $1.18 | $1.42 | +0.00% |
| August 2026 | $0.9639 | $1.17 | $1.47 | -1.12% |
| September 2026 | $1.03 | $1.26 | $1.63 | +8.37% |
| October 2026 | $1.05 | $1.30 | $1.70 | +2.91% |
| November 2026 | $0.9912 | $1.25 | $1.65 | -4.32% |
| December 2026 | $0.9829 | $1.25 | $1.68 | +0.14% |
Click any year to see its month-by-month GOVX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, GOVX is projected to trade between $1.05 and $1.68, averaging $1.18 — a potential gain of 0% from today's $1.18. A consolidation phase looks the most probable path here.
GeoVax Labs, Inc.'s 2027 outlook centres on $1.06, within a $0.7682 to $1.58 range. That is -10% versus the projected 2026 average. That marks a -10% change versus current levels. Price action looks broadly range-bound.
By 2028, GOVX could reach as high as $1.57, with a base case around $0.9863 and support toward $0.6735 — roughly -16% from $1.18. Expect choppier, lower action through this leg of the cycle.
Expect GOVX to range from $0.6209 to $1.60 through 2029. The $0.9579 average target implies a -19% move from current prices. That is -3% versus the projected 2028 average. A cyclical pullback looks likely — prices rarely move in a straight line.
The GOVX price prediction for 2030 points to an average of $1.01 (low $0.6246, high $1.75) — a potential decline of -14% on today's $1.18. A consolidation phase looks the most probable path here.
In 2031, GOVX is projected to trade between $0.7753 and $2.35, averaging $1.31 — a potential gain of +11% from today's $1.18. That is up +30% on the projected 2030 average. Price action looks broadly range-bound.
GeoVax Labs, Inc.'s 2032 outlook centres on $1.39, within a $0.7886 to $2.58 range. That is up +6% on the projected 2031 average. That marks a +18% change versus current levels. A consolidation phase looks the most probable path here.
By 2033, GOVX could reach as high as $2.81, with a base case around $1.48 and support toward $0.8042 — roughly +25% from $1.18. Momentum favours further upside here.
Expect GOVX to range from $0.7048 to $2.63 through 2034. The $1.35 average target implies a +14% move from current prices. That is -9% versus the projected 2033 average. A consolidation phase looks the most probable path here.
The GOVX price prediction for 2035 points to an average of $1.05 (low $0.5301, high $2.10) — a potential decline of -11% on today's $1.18. Price action looks broadly range-bound.
In 2040, GOVX is projected to trade between $0.757 and $3.69, averaging $1.68 — a potential gain of +43% from today's $1.18. That is up +60% on the projected 2035 average. Buyers look set to stay in control over this stretch.
GeoVax Labs, Inc.'s 2050 outlook centres on $3.34, within a $1.50 to $7.69 range. That is up +99% on the projected 2040 average. That marks a +183% change versus current levels. Momentum favours further upside here.
Investing $1,000 in GOVX today (≈ 847.457627 GOVX) could be worth
$2,834.09
+$1,834.09 (+183%) by 2050 · US Dollar
Based on the average projected GOVX price of $3.34 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in GOVXwould be worth at today's price.
$1,000 invested in GOVX on Jul 10, 2025 (≈ 59.970018 GOVX) would be worth
$70.76
-$929.24 (-92.9%) today · 0.07× · US Dollar
Based on a GOVX entry price of $16.67 vs. today's $1.18.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.19 | $991.6 | -0.8% |
| 1 month ago | $1.2 | $983.33 | -1.7% |
| 3 months ago | $1.23 | $959.35 | -4.1% |
| 6 months ago | $3.57 | $330.53 | -66.9% |
| 1 year ago | $16.67 | $70.76 | -92.9% |
| All time (5.0y) ago | $1,556.25 | $0.76 | -99.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our GOVX forecast.
Our base-case forecast reaches $2.40 around 2050.
Implied market cap at $2.40: $12.51M
The multi-year forecast shows a mixed path with notable upside potential later in the horizon. For 2026 the average is projected at $1.19 with a 0% ROI and NEUTRAL sentiment, suggesting a flat near-term outlook.
Through 2027–2029 the model indicates continued pressure, with 2027 average $1.06 and ROI -11.3%, 2028 average $0.979 and ROI -17.7%, and 2029 average $0.9999 with ROI -16, signaling bearish tendencies in the mid-term.
In 2030 the average is $1.00 with ROI -15.7 and BEARISH sentiment, followed by an inflection toward modest gains in 2031–2033: 2031 average $1.31 (ROI 9.9, NEUTRAL), 2032 average $1.45 (ROI 21.6, BULLISH), and 2033 average $1.47 (ROI 23.5, BULLISH).
The forecast improves into 2040, with average $1.70 and ROI 42.6 (BULLISH), and remains favorable into 2050, where the average is $3.45 and the max reaches $7.94 (ROI 190, BULLISH).
These are estimates of potential paths, not guarantees. The outlook shows meaningful upside potential later in the horizon but also meaningful downside risk in the earlier years.
Tap a question to reveal the answer.
2030: min $0.6198, avg $1.00, max $1.74; ROI -15.7; sentiment BEARISH.
The forecast shows a mixed path: near-term years (2026–2029) broadly hover around the $1 range with negative ROI in 2027–2030, followed by bullish prospects in 2032–2033 and a strong upside in 2040 and 2050 (max values up to $3.73 in 2040 and $7.94 in 2050). These are estimates and involve substantial uncertainty.
Yes. The 2040 max is $3.73 and the 2050 max is $7.94, indicating that a price of $3 is within the forecasted upside potential.
Sentiment: NEUTRAL. RSI(14): 40. SMA(50): $1.59. SMA(200): $5.61. Support: $1.17. Resistance: $3.64. 30-day range: $0.7571 to $1.87.
Current price: $1.19. Market cap: $6.2M. Rank: 5112.
GeoVax Labs, Inc. Community Discussion
0Share your GeoVax Labs, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.